OrbiMed Leads in Immune Drug Discovery
20 May 2026
US$ 20.00
OrbiMed Advisors LLC has led the US$50 m series C funding round of Accro Bioscience Inc (Accro), joined by ......
Related Publications
Subscribers’ Weekly ending 22 May 2026...
InCred Alternative Investments, through its private equity funds, has invested 1.9 bn rupees (US$19 m) into VEM...
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.